Taking the question as asked, rather than the general version of it. The shortage clause is the answer to the second question and it is a subtraction rather than an addition. Both exemptions forbid compounding something that is essentially a copy of a commercially available approved product. A product FDA has listed as in shortage is not treated as commercially available, so listing removed the objection that otherwise blocked compounding. It never created a permission; it withdrew a prohibition, which is why it evaporated the moment the supply fact changed.
My pharmacy stopped supplying with three weeks notice and a letter that explained nothing, so I went and read the statute.
The question I want answered is what actually distinguishes 503A from 503B, in terms of what each may make and from what starting material.
Not looking for reassurance. Looking for the part I have got wrong.
Dr.ObesityMed said:The shortage clause is the answer to the second question and it is a subtraction rather than an addition.
Agreeing with Dr.ObesityMed, and the qualification matters more than the agreement. Worth adding the genuine exception, because it is real and narrow: a change made for an identified patient where the prescriber determines it produces a significant clinical difference for that patient. A grid of fixed doses offered to everybody is not that, whatever the intake form says.
PeptideMeter — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View Resultsrobert_kc said:My pharmacy stopped supplying with three weeks notice and a letter that explained nothing, so I went and read the statute.
Can confirm the pattern robert_kc describes. They are two different exemptions from the same federal requirements and they buy different things. A 503A pharmacy is regulated primarily by the state board, needs a patient-specific prescription, is exempt from CGMP, and may use a bulk substance that has a USP monograph, is a component of an approved drug, or appears on the 503A bulks list — three independent doorways. A 503B outsourcing facility registers with the FDA, is inspected on a risk basis, must comply with CGMP, may compound for office stock without a patient-specific prescription, and has one doorway to a permitted bulk substance: the 503B bulks list, or the drug shortage list.
From the other side of the consultation, briefly.
Price comparison for compounded supply across sources I've used:
| Source | Monthly Cost | Type | Purity Verified |
|---|---|---|---|
| Brand (Ozempic) | $1022 | FDA-approved | N/A (pharma) |
| 503B Compounding | $152 | cGMP compounded | Yes (in-house) |
| 503A Compounding | $92 | Patient-specific | Varies |
| Research peptide | $62 | Not for human use | Often Janoshik |
I use the 503B option — best balance of quality, cost, and legality. The brand price is insane but insurance can help if you qualify.